Anchored in work undertaken by one of the founding principals and an associate at Clemson University, Elastrin Therapeutics is a young biotech addressing development of novel therapies to reverse cardiovascular disease - to restore hardened/damaged arteries and tissue to healthy resilience by targeting the elastic fiber that makes them work. The assembled team has built a proprietary platform that restores degraded elastin by effectively removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. The platform further significantly improves the efficacy of drugs and eliminates side-effects by combining particle design with elastin targeting. As the firm's webiste notes, they are: Leveraging a platform technology to develop therapeutics targeting damaged elastin fiber, rendering calcified tissue and organs supple again.
